9.31
0.08 (0.87%)
| Previous Close | 9.23 |
| Open | 9.23 |
| Volume | 346,488 |
| Avg. Volume (3M) | 360,947 |
| Market Cap | 376,325,600 |
| Price / Earnings (Forward) | 500.00 |
| Price / Sales | 0.460 |
| Price / Book | 0.880 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Profit Margin | -17.78% |
| Operating Margin (TTM) | -17.64% |
| Diluted EPS (TTM) | -3.70 |
| Quarterly Revenue Growth (YOY) | 2.70% |
| Total Debt/Equity (MRQ) | 42.06% |
| Current Ratio (MRQ) | 2.71 |
| Operating Cash Flow (TTM) | 25.99 M |
| Levered Free Cash Flow (TTM) | 67.13 M |
| Return on Assets (TTM) | -5.00% |
| Return on Equity (TTM) | -27.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Orthofix Medical Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | 3.0 |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.30 |
|
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 2.79% |
| % Held by Institutions | 87.90% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAZAAR ALAN LEE | 9.73 | - | 14,965 | 145,609 |
| BURRIS WAYNE | 9.73 | - | 14,965 | 145,609 |
| CAPPS VICKIE L | 9.73 | - | 14,965 | 145,609 |
| FINEGAN MICHAEL | 9.73 | - | 20,721 | 201,615 |
| HANNON JASON | 9.73 | - | 14,965 | 145,609 |
| HENNEMAN JOHN B III | 9.73 | - | 14,965 | 145,609 |
| KUMMETH CHARLES R. | 9.73 | - | 14,965 | 145,609 |
| MANIAR SHWETA | 9.73 | - | 14,965 | 145,609 |
| PAOLUCCI MICHAEL E | 9.73 | - | 14,965 | 145,609 |
| Aggregate Net Quantity | 140,441 | |||
| Aggregate Net Value ($) | 1,366,491 | |||
| Aggregate Avg. Buy ($) | 9.73 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PAOLUCCI MICHAEL E | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
| MANIAR SHWETA | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
| BURRIS WAYNE | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
| HENNEMAN JOHN B III | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
| CAPPS VICKIE L | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
| FINEGAN MICHAEL | Director | 10 Jun 2026 | Acquired (+) | 20,721 | 9.73 | 201,615 |
| HANNON JASON | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
| KUMMETH CHARLES R. | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
| BAZAAR ALAN LEE | Director | 10 Jun 2026 | Acquired (+) | 14,965 | 9.73 | 145,609 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |